What the studies show
Not studied. The approved population is not a proxy for the general public.
Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.
In context
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, approved in the United States to reduce excess abdominal fat in people with HIV-associated lipodystrophy. In that population it cuts visceral fat by about 15% over six months, and the fat returns when treatment stops. Its use for general fat loss, muscle or anti-ageing rests on extrapolation from that specific group; there are no trials in healthy adults. It is not authorised in the EU.
Tesamorelin is approved (rx, us). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Tesamorelin proven to help with fat loss in healthy adults?
What studies are behind the grade?
Is Tesamorelin approved for this?
Other outcomes for Tesamorelin
- AVisceral fat (HIV lipodystrophy)2 phase 3 RCTs (n=816)
- BLiver fat (HIV with NAFLD)1 RCT (n=61)
- CCognition in older adults1 RCT (n=152)
- AIGF-1 elevation and glucose effectsadversePhase 3 programme
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →